Drug
Mgd024
Mgd024: highest development phase Phase 1, developed by MacroGenics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- MacroGenics
Trials
| Drug | Phase | Indication |
|---|---|---|
| MGD024 NCT05362773 | Phase 1 | Leukemia, Acute Myeloid |
Latest
No recent events.
Follow Mgd024 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.